FRA:E8TN (France)
Â
Bearer and/or Registered shares issued from reverse split
€
25.60
(+0.2%)
Nov 8
Business Description
Eurobio Scientific
ISIN : FR0013240934
Share Class Description:
FRA:E8TN: Bearer and/or Registered shares issued from reverse splitCompare
Compare
Traded in other countries / regions
ALERS.FranceE8TN.GermanyDXNHF.USA IPO Date
2020-04-07Description
Eurobio Scientific is one of the leading providers of specialty in vitro diagnostics and life-science solutions. The product portfolio includes Tetanos Quick Stick, BJI InoPlex, AlloMap, and TEDAC Consortium.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.92 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.53 | |||||
| Debt-to-EBITDA | 3.23 | |||||
| Interest Coverage | 3.03 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.98 | |||||
| Beneish M-Score | -3.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -11.5 | |||||
| 3-Year EBITDA Growth Rate | -33.9 | |||||
| 3-Year EPS without NRI Growth Rate | -57 | |||||
| 3-Year FCF Growth Rate | -24.3 | |||||
| 3-Year Book Growth Rate | 22.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 38.43 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.25 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.96 | |||||
| 9-Day RSI | 57.67 | |||||
| 14-Day RSI | 64.34 | |||||
| 6-1 Month Momentum % | 78.22 | |||||
| 12-1 Month Momentum % | 60.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.69 | |||||
| Quick Ratio | 2.26 | |||||
| Cash Ratio | 1.59 | |||||
| Days Inventory | 98.89 | |||||
| Days Sales Outstanding | 66.79 | |||||
| Days Payable | 52.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 4 | |||||
| Shareholder Yield % | 6.15 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 46.18 | |||||
| Operating Margin % | 8.91 | |||||
| Net Margin % | 4.59 | |||||
| FCF Margin % | 13.79 | |||||
| ROE % | 3.77 | |||||
| ROA % | 2.11 | |||||
| ROIC % | 3.95 | |||||
| 3-Year ROIIC % | -54.26 | |||||
| ROC (Joel Greenblatt) % | 41.13 | |||||
| ROCE % | 5.39 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 41.69 | |||||
| Forward PE Ratio | 23.11 | |||||
| PE Ratio without NRI | 36.98 | |||||
| Shiller PE Ratio | 30.39 | |||||
| Price-to-Owner-Earnings | 12.42 | |||||
| PEG Ratio | 0.81 | |||||
| PS Ratio | 1.96 | |||||
| PB Ratio | 1.45 | |||||
| Price-to-Tangible-Book | 9.01 | |||||
| Price-to-Free-Cash-Flow | 14.86 | |||||
| Price-to-Operating-Cash-Flow | 12.76 | |||||
| EV-to-EBIT | 18.67 | |||||
| EV-to-EBITDA | 9.11 | |||||
| EV-to-Revenue | 1.84 | |||||
| EV-to-FCF | 13.36 | |||||
| Price-to-Projected-FCF | 0.56 | |||||
| Price-to-Median-PS-Value | 2.1 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.99 | |||||
| Price-to-Graham-Number | 3.85 | |||||
| Price-to-Net-Current-Asset-Value | 22.07 | |||||
| Earnings Yield (Greenblatt) % | 5.35 | |||||
| FCF Yield % | 7.72 | |||||
| Forward Rate of Return (Yacktman) % | 30.45 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eurobio Scientific Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 144.727 | ||
| EPS (TTM) (€) | 0.62 | ||
| Beta | 0.96 | ||
| Volatility % | 48.09 | ||
| 14-Day RSI | 64.34 | ||
| 14-Day ATR (€) | 0.059964 | ||
| 20-Day SMA (€) | 25.5775 | ||
| 12-1 Month Momentum % | 60.47 | ||
| 52-Week Range (€) | 13.6 - 25.7 | ||
| Shares Outstanding (Mil) | 10.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eurobio Scientific Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eurobio Scientific Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eurobio Scientific Frequently Asked Questions
What is Eurobio Scientific(FRA:E8TN)'s stock price today?
The current price of FRA:E8TN is €25.60. The 52 week high of FRA:E8TN is €25.70 and 52 week low is €13.60.
When is next earnings date of Eurobio Scientific(FRA:E8TN)?
The next earnings date of Eurobio Scientific(FRA:E8TN) is .
Does Eurobio Scientific(FRA:E8TN) pay dividends? If so, how much?
Eurobio Scientific(FRA:E8TN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers